OS Therapies NYSE American: OSTX
@OSTherapies
Followers
277
Following
48
Media
125
Statuses
203
The leading Osteosarcoma technology company focused on the development and commercialization of treatments for Osteosarcoma. NYSE: $OSTX
Rockville, Maryland
Joined May 2022
OS Therapies provides positive EMA regulatory update following positive rapporteur meeting. Rapporteur highlights potential broader benefits of OST-HER2 in pulmonary and primary osteosarcoma settings, supported by translational canine data from the University of Pennsylvania.
0
1
0
Today, OS Therapies Advisor, Borys Shor, Ph.D., Advisor, joined Bioprocess Online Live for an in-depth conversation with leading ADC experts to discuss antibody-drug conjugates (ADCs) that are reshaping oncology pipelines and why these innovations demand new ways of thinking
0
0
4
OS Therapies announces its participation in upcoming October 2025 conferences and events. Details available in the press release: https://t.co/4jR7o2hR9n $OSTX #BusinessUpdate
0
1
6
Join Bioprocess Online Live, for an in-depth conversation with leading ADC experts including OS Therapies, Advisor, Borys Shor, Ph.D., Advisor, OS Therapies. Tuesday, October 7, 2025 | 11 AM ET Next-Gen ADCs Demand New CMC Approaches — Are You Ready? Register here:
0
0
2
OS Therapies Chief Medical & Scientific Officer, Dr. Robert Petit, discusses how OST-504 is designed to harness the immune system against prostate cancer in a meaningful discussion with Cell & Gene Editor-In-Chief @ErinHarris_1. Read the article highlighting prostate cancer
0
1
3
OS Therapies provides a regulatory update on its plans for filing marketing authorizations in the US and UK for OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic #osteosarcoma based on data generated from its completed Phase 2b clinical trial,
0
2
1
OS Therapies CBO Gerald Commissiong will be participating in a spotlight panel "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics,” during #BioFuture2025 at @cure345 in #NewYorkCity on October 13, 2025. If you’re attending and interested in setting up a
1
6
36
OS Therapies to Participate in Spotlight Panel at #BioFuture2025 October 13 11:00am EDT. Company management will provide an overview of OS Therapies, with a particular emphasis on the clinical development and commercial plans for OST-HER2. More details can be found in the press
0
2
3
New article from @pharmabiznews: OS Therapies completes patient enrolment in OST-504 phase 1b prostate cancer clinical trial. If you missed our latest announcement, dive in here: https://t.co/0lOY1bcXnL $OSTX #Biotech #ClinicalResearch
0
2
6
OS Therapies completes final patient visit in OST-504 phase-1b prostate cancer trial. Read more via @Benzinga: https://t.co/nwBnxqoQ9f $OSTX #Oncology
benzinga.com
Clinical data from Phase 1b prostate cancer trial to be released in Q4/25Additionally, updated 2-year overall survival data from all 40 patients in the Phase 2b clinical trial of OST-HER2 in the...
0
1
7
OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit. Read the press release here: https://t.co/XElDf9GI0a $OSTX #ClinicalResearch #Biotech
0
2
7
ICYMI: $OSTX provided stakeholders with a detailed update regarding OST-HER2 recurrent, fully resected, pulmonary metastatic osteosarcoma program following a highly productive End of Phase 2 Meeting with FDA. We remain on track to begin rolling BLA submission in September 2025.
0
1
8
OS Therapies featured in @CancerNetwrk’s ‘In The News’ highlighting our end of phase 2 meeting with the FDA to discuss OST-HER2 in development for our Metastatic Osteosarcoma Program. Read more: https://t.co/Ad8cmH5EBU $OSTX #OncNews
cancernetwork.com
Updates on treatments like vusolimogene oderparepvec for advanced melanoma, and novel therapies have been provided by the FDA.
1
1
7
OS Therapies is looking forward to participating in upcoming investor conferences in September 2025, including: • Cantor Global Healthcare Conference 2025 • H.C. Wainwright 27th Annual Global Investment Conference • Lake Street Capital Markets 9th Annual Best Ideas Growth
0
2
10
OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting. Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food & Drug
1
3
9
Reminder: OS Therapies will provide OST-HER2 recurrent, fully resected, pulmonary metastatic osteosarcoma FDA end of phase 2 meeting update on Tuesday, September 2, 2025. $OSTX https://t.co/Ywe1KUqzRu
1
2
5
OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025. Read the press release: https://t.co/Ywe1KUqzRu $OSTX
0
4
14